...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion.
【24h】

Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion.

机译：胺碘酮预防转律后症状性阵发性和持续性心房颤动复发的功效。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: It has been previously reported that the efficacy of class I antiarrhythmics in preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation (AF) is limited when AF lasts for 48 h or more. However, it is unclear whether the efficacy of amiodarone, a class III drug, is superior to class I antiarrhythmics in patients with long-lasting AF. METHOD AND RESULTS: The relationship between the duration of tachycardia and the efficacy of amiodarone in preventing recurrence of tachycardia was examined in 55 patients (37 men, 18 women, mean age 68+/-9 years) to whom amiodarone was administered after electrical or pharmacological cardioversion for paroxysmal and persistent AF. In 26 patients, paroxysmal and persistent AF ceased within 48 h after onset (Group A), and in the other 29 patients, it ceased after 48 h (Group B). Patient characteristics and actuarial recurrence-free rates were compared between the 2 groups. The mean follow-up period was 30+/-11 months. No statistically significant difference between the groups was found in patient characteristics. Actuarial recurrence-free rates in Group A and B at 1, 3, 6, 9, and 12 months were 100%, 81%, 69%, 62%, and 54%, and 93%, 79%, 66%, 52%, and 48%, respectively (p=NS at 12 months). The period of maintenance of sinus rhythm was 14.7+/-3.2 months in group A and 13.3+/-3.3 months in group B (mean+/-SE, p=NS). CONCLUSION: In the case of amiodarone, efficacy for maintaining sinus rhythm after cardioversion of AF was not biased by the duration of arrhythmia. This observation suggests amiodarone is effective in maintaining normal sinus rhythm after cardioversion, even in patients with long-lasting AF and electrical atrial remodeling.
机译：背景：先前已有报道，当房颤持续48小时或更长时间时，I类抗心律失常药在预防症状性阵发性和持续性心房颤动（AF）复发方面的疗效有限。但是，目前尚不清楚在持续性房颤患者中，胺碘酮（III类药物）的疗效是否优于I类抗心律不齐药物。方法和结果：检查了55例接受电或手术后胺碘酮治疗的患者（37例男性，18例女性，平均年龄68 +/- 9岁）中心动过速的持续时间与胺碘酮预防心动过速复发的疗效之间的关系。阵发性和持续性房颤的药理心脏复律。在26例患者中，阵发性和持续性AF在发作后48小时内停止（A组），而在其他29例患者中，其在48小时后停止（B组）。比较两组的患者特征和无精算复发率。平均随访期为30 +/- 11个月。两组患者的特征没有统计学上的显着差异。 A，B组在1,3、6、9和12个月的无精算无复发率分别为100％，81％，69％，62％和54％，以及93％，79％，66％，52分别为％和48％（p = 12个月时的NS）。 A组的窦性心律维持期为14.7 +/- 3.2个月，B组为13.3 +/- 3.3个月（平均值+/- SE，p = NS）。结论：对于胺碘酮，房颤复律后维持窦性心律的疗效不受心律失常持续时间的影响。该观察结果表明，胺碘酮在复律后仍可有效维持正常的窦性心律，即使在具有持续性房颤和心房重构的患者中也是如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号